According to a new report, published by KBV research, The Global Digital Dose Inhaler Market size is expected to reach $49 billion by 2030, rising at a market growth of 19.6% CAGR during the forecast period.
The Dry Powder Inhaler (DPI) segment would witness a CAGR of 21% during (2023 - 2030). Dried powder inhalers are devices that administer medication as a dried powder to the airways. The prevalence of chronic respiratory diseases such as COPD, Asthma, etc., and the increasing demand for technology-enabled features of respiratory devices are the primary factors driving the growth of the dry powder inhaler segment.
The Branded Medication segment is leading the Global Digital Dose Inhaler Market by Type in 2022; thereby, achieving a market value of $30.3 billion by 2030. This results from rising healthcare expenditure and demand for new respiratory medications. In actuality, the anticipated penetration rate of such devices in the technology field is responsible for both the continued development of inhalation medications and the rise in branded drug inhalation.
The Asthma segment is experiencing a CAGR of 19.8% during (2023 - 2030). The prevalence of asthma is rising, particularly among the elderly population. Inhalers are the only means of controlling asthma. Digital dose inhalers provide asthmatic patients with a method for administering the controlled dosage.
The North America region dominated the Global Digital Dose Inhaler Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $20.4 billion by 2030. The Europe market is poised to grow at a CAGR of 19.1% during (2023 - 2030). Additionally, The Asia Pacific market would witness a CAGR of 20.7% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/digital-dose-inhaler-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Sensirion AG, Teva Pharmaceuticals Industries Ltd., OPKO Health, Inc., Propeller Health (ResMed, Inc.), Novartis AG, AstraZeneca PLC, Glenmark Pharmaceuticals Limited, Beximco Pharmaceuticals Ltd., GlaxoSmithKline PLC and Mundipharma Deutschland GmbH & Co. KG.
By Product
By Type
By Indication
By Geography
Companies Profiled
Unique Offerings 
